$KITT
Nauticus Robotics, Inc. Stock $kitt

$kitt Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000121390023066523 Filed on August 14, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$1.594M	$1.128M	$0.00
YoY Change	-46.54%
Cost Of Revenue	$2.651M	$1.901M	$2.540M
YoY Change	-29.88%	-25.17%	73.58%
Gross Profit	-$1.058M	-$772.5K	-$2.540M
YoY Change	32.25%	-69.59%	73.58%
Gross Profit Margin	-66.35%	-68.48%
Selling, General & Admin	$6.705M	$5.560M	$76.03K
YoY Change	37.96%	7212.9%
% of Gross Profit
Research & Development	$275.2K	$482.8K	$583.9K
YoY Change	13.23%	-17.32%	25.07%
% of Gross Profit
Depreciation & Amortization	$157.0K	$60.00K
YoY Change	-57.55%
% of Gross Profit
Operating Expenses	$275.2K	$482.8K	$1.522M
YoY Change	13.23%	-68.29%
Operating Profit	-$8.198M	-$6.869M	-$1.522M
YoY Change	35.6%	351.17%
Interest Expense	-$957.4K	-$1.540M	$739.0K
YoY Change	-168.29%	-308.38%
% of Operating Profit
Other Income/Expense, Net	-$9.480M	$27.54M	-$834.4K
YoY Change	24954.1%	-3401.03%	-236.8%
Pretax Income	-$17.68M	$20.67M	-$783.5K
YoY Change	34.13%	-2738.26%
Income Tax			$12.36K
% Of Pretax Income
Net Earnings	-$17.68M	$20.67M	-$795.8K
YoY Change	190.59%	-2697.72%
Net Earnings / Revenue	-1109.18%	1832.56%
Basic Earnings Per Share	-$0.43	$0.52	-$0.04
Diluted Earnings Per Share	-$0.43	$0.49	-$0.04
COMMON SHARES
Basic Shares Outstanding	49.82M shares	47.51M shares	21.56M shares
Diluted Shares Outstanding	41.16M shares	44.35M shares	21.56M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.772M	$4.400M	$174.7M
YoY Change	-81.14%	-97.48%	698524.11%
Cash & Equivalents	$6.772M	$4.353M	$172.8K
Short-Term Investments	$0.00	$0.00	$174.5M
Other Short-Term Assets	$584.5K	$53.61K	$30.16K
YoY Change	-76.58%	77.74%
Inventory	$13.96M	$12.54M	$2.380M
Prepaid Expenses	$5.126M	$6.121M	$30.16K
Receivables	$997.4K	$1.302M	$1.605M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$27.87M	$25.23M	$202.9K
YoY Change	-41.89%	12331.1%	711.77%
LONG-TERM ASSETS
Property, Plant & Equipment	$26.28M	$21.78M	$6.238M
YoY Change	172.4%	249.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$104.9K	$129.4K	$174.5M
YoY Change	34.62%	-99.93%	78524.39%
Total Long-Term Assets	$28.47M	$23.30M	$174.5M
YoY Change	182.12%	-86.65%	78524.39%
TOTAL ASSETS
Total Short-Term Assets	$27.87M	$25.23M	$202.9K
Total Long-Term Assets	$28.47M	$23.30M	$174.5M
Total Assets	$56.34M	$48.53M	$174.7M
YoY Change	-2.94%	-72.22%	70646.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.713M	$5.732M	$325.4K
YoY Change	105.02%	1661.52%
Accrued Expenses	$6.475M	$7.310M	$1.019M
YoY Change	452.65%	617.39%	2443.0%
Deferred Revenue	$152.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$400.3K
YoY Change		-100.0%	118.93%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$12.96M	$13.57M	$1.958M
YoY Change	197.29%	592.84%	778.36%
LONG-TERM LIABILITIES
Long-Term Debt	$29.93M	$17.80M	$0.00
YoY Change	46.49%
Other Long-Term Liabilities	$14.50M	$5.847M	$5.056M
YoY Change	-55.24%	15.65%
Total Long-Term Liabilities	$44.43M	$23.65M	$5.056M
YoY Change	117.49%	367.71%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.96M	$13.57M	$1.958M
Total Long-Term Liabilities	$44.43M	$23.65M	$5.056M
Total Liabilities	$59.01M	$38.21M	$7.014M
YoY Change	102.7%	444.71%	3046.43%
SHAREHOLDERS EQUITY
Retained Earnings	-$79.25M	-$61.57M	-$6.699M
YoY Change	50.12%	819.08%
Common Stock	$4.986K	$4.789K	$431.00
YoY Change	5.52%	1011.14%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)			$944.9K
YoY Change
Treasury Stock Shares			271.6K shares
Shareholders Equity	-$2.676M	$10.32M	-$6.699M
YoY Change
Total Liabilities & Shareholders Equity	$56.34M	$48.53M	$174.7M
YoY Change	-2.94%	-72.22%	70646.07%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$17.68M	$20.67M	-$795.8K
YoY Change	190.59%	-2697.72%
Depreciation, Depletion And Amortization	$157.0K	$60.00K
YoY Change	-57.55%
Cash From Operating Activities	-$3.466M	-$4.140M	-$256.9K
YoY Change	-88.74%	1511.33%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$4.646M	-$4.610M
YoY Change	-31.78%
Cash From Investing Activities	-$4.646M	-$4.610M
YoY Change	-31.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.53M	620.0K	133.3K
YoY Change	-80.11%	365.01%
NET CHANGE
Cash From Operating Activities	-3.466M	-4.140M	-256.9K
Cash From Investing Activities	-4.646M	-4.610M
Cash From Financing Activities	10.53M	620.0K	133.3K
Net Change In Cash	2.414M	-8.130M	-123.6K
YoY Change	-84.25%	6477.67%
FREE CASH FLOW
Cash From Operating Activities	-$3.466M	-$4.140M	-$256.9K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Address City Or Town EntityAddressCityOrTown	WEBSTER
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77598
	dei	City Area Code CityAreaCode	(281)
	dei	Local Phone Number LocalPhoneNumber	942-9069
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40611
	dei	Entity Registrant Name EntityRegistrantName	NAUTICUS ROBOTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-1699753
	dei	Entity Address Address Line1 EntityAddressAddressLine1	17146 FEATHERCRAFT LANE
	dei	Entity Address Address Line2 EntityAddressAddressLine2	SUITE 450
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	49820918	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4353179	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17787159	usd
CY2023Q2	us-gaap	Deposits Assets Current DepositsAssetsCurrent	250375	usd
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	250375	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	4959263	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1302494	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1622434	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	12536004	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	6666912	usd
CY2023Q2	us-gaap	Contract With Customer Asset Gross Current ContractWithCustomerAssetGrossCurrent	611236	usd
CY2022Q4	us-gaap	Contract With Customer Asset Gross Current ContractWithCustomerAssetGrossCurrent	573895	usd
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6121038	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5046599	usd
CY2023Q2	us-gaap	Other Assets Current OtherAssetsCurrent	53605	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	56410	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	25227931	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	36963047	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21784483	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15167367	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1384779	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	317208	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	129370	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	155490	usd
CY2023Q2	us-gaap	Assets Assets	48526563	usd
CY2022Q4	us-gaap	Assets Assets	52603112	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	5731767	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	324484	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7310051	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3142977	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	524279	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	410158	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	13566097	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3877619	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5847057	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	32688342	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	992660	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	87214	usd
CY2023Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	17800494	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	15922118	usd
CY2023Q2	us-gaap	Liabilities Liabilities	38206308	usd
CY2022Q4	us-gaap	Liabilities Liabilities	52575293	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	625000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	625000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47894251	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47250771	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47894251	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47250771	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	4789	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	4725	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	71885793	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	68128196	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-61570327	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-68105102	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	10320255	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	27819	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	48526563	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	52603112	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1128115	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2796159	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3948395	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5032124	usd
CY2022Q2	kitt	Service Related Party ServiceRelatedParty	193400	usd
	kitt	Service Related Party ServiceRelatedParty	500	usd
	kitt	Service Related Party ServiceRelatedParty	193400	usd
CY2023Q2	us-gaap	Revenues Revenues	1128115	usd
CY2022Q2	us-gaap	Revenues Revenues	2989559	usd
	us-gaap	Revenues Revenues	3948895	usd
	us-gaap	Revenues Revenues	5225524	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	1900602	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	2540062	usd
	us-gaap	Cost Of Revenue CostOfRevenue	4832869	usd
	us-gaap	Cost Of Revenue CostOfRevenue	4439223	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	53209	usd
CY2022Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	117086	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	326308	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	228405	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	482761	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	583870	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	709728	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1851282	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5560565	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2271138	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10773209	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3917179	usd
CY2023Q2	us-gaap	Costs And Expenses CostsAndExpenses	7997137	usd
CY2022Q2	us-gaap	Costs And Expenses CostsAndExpenses	5512156	usd
	us-gaap	Costs And Expenses CostsAndExpenses	16642114	usd
	us-gaap	Costs And Expenses CostsAndExpenses	10436089	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6869022	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2522597	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12693219	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5210565	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-746	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	9453	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1153127	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5241	usd
CY2023Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	3908	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	3908	usd
CY2023Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	17709	usd
CY2022Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	9848	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	27593	usd
CY2023Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-590266	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-590266	usd
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-29668454	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-27431550	usd
CY2023Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1556597	usd
CY2022Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-853660	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-6491664	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1655634	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	27542462	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-834359	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	19227994	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1650393	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	20673440	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-3356956	usd
	us-gaap	Net Income Loss NetIncomeLoss	6534775	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6860958	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.52
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.16
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.71
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.49
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.35
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.16
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.71
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39963266	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9669217	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9669217	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39872864	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9669217	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44345319	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9669217	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40602678	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9669217	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-6611457	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	200157	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3504002	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-9915302	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	188657	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-3356956	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-13083601	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	27819	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1214863	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	59189	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-14138665	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-12836794	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1862164	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	283390	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	338055	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	20673440	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	10320255	usd
	us-gaap	Net Income Loss NetIncomeLoss	6534775	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6860958	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	326308	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	228405	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1878376	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	347106	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3077027	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	388814	usd
	us-gaap	Extinguishment Of Debt Gain Loss Income Tax ExtinguishmentOfDebtGainLossIncomeTax	590266	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-27431550	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	145253	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	88212	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-319940	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	811016	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5869092	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2380429	usd
	us-gaap	Increase Decrease In Commodity Contract Assets And Liabilities IncreaseDecreaseInCommodityContractAssetsAndLiabilities	37341	usd
	us-gaap	Increase Decrease In Commodity Contract Assets And Liabilities IncreaseDecreaseInCommodityContractAssetsAndLiabilities	60585	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1045514	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1360086	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	8733185	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1039296	usd
	us-gaap	Increase Decrease In Notes Payable Current IncreaseDecreaseInNotesPayableCurrent	-373791	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	193257	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	155382	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12971624	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9910414	usd
	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	6102253	usd
	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	3080199	usd
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	4959263	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1142990	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3080199	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	342579	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	338055	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	680634	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-13433980	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12990613	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17787159	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20952867	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4353179	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7962254	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	908184	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	761189	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	841171	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1949142	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1212824	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1212824	usd
	kitt	Shares Issued Description SharesIssuedDescription	follows (i) an aggregate of 36,650,778 shares of Common Stock, par value $0.0001 (the “Common Stock” of CLAQ prior to the Closing, and the Common Stock of Nauticus following the Closing) shares were issued to holders of Nauticus Common Stock in the Business Combination (ii) the right to receive 7,499,993 additional shares of Common Stock held in escrow pursuant to the terms of the Merger Agreement and as further described below (such additional escrowed shares, the “Earnout Shares”) and (iii) the issuance of 3,100,000 shares of Common Stock for the Equity Financing (as described below). An aggregate of 47,250,771 shares of Common Stock (inclusive of the Earnout Shares) was issued after the Business Combination.
CY2023Q2	kitt	Additional Share Of Common Stock AdditionalShareOfCommonStock	7499993	shares
	us-gaap	Intercompany Agreements Description IntercompanyAgreementsDescription	i.one-half of the Earnout Shares will be released if, within a 5-year period from Closing Date, the volume-weighted average price of our Common Stock equals or exceeds $15.00 per share over any 20 trading days within a 30-day trading period; ii.one-quarter of the Earnout Shares will be released if, within a 5-year period from Closing Date, the volume-weighted average price of our Common Stock equals or exceeds $17.50 per share over any 20 trading days within a 30-day trading period; and iii.one-quarter of the Earnout Shares will be released if, on or after December 31, 2022, within a 5-year period from Closing Date, the volume-weighted average price of our Common Stock equals or exceeds $20.00 per share over any 20 trading days within a 30-day trading period.
CY2023Q2	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	3100000	shares
	us-gaap	Common Stock Convertible Conversion Price Decrease CommonStockConvertibleConversionPriceDecrease	10
	us-gaap	Stockholders Equity Other StockholdersEquityOther	31000000	usd
CY2023Q2	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	36530320	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	3.28
CY2023Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	165713	shares
CY2022Q3	us-gaap	Investment Owned Underlying Face Amount At Market Value InvestmentOwnedUnderlyingFaceAmountAtMarketValue	14947875	usd
CY2022Q3	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	30157	usd
CY2022Q3	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	14796942	usd
CY2022Q2	kitt	Antidilutive Securities Excluded From Computation Of Earnings Per Share Earnout Shares AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareEarnoutShares		shares
CY2022Q3	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	850333	usd
CY2022Q3	us-gaap	Temporary Equity Net Income TemporaryEquityNetIncome	-669243	usd
CY2023Q2	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	14947875	usd
CY2023Q2	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	12582000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents And Federal Funds Sold CashCashEquivalentsAndFederalFundsSold	4400000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b> – The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include the (i) estimates of future costs to complete customer contracts recognized over time, (ii) valuation allowances for deferred income tax assets, (iii) valuation of stock-based compensation awards and (iv) the valuation of conversion options, warrants and earnouts. Actual results could differ from those estimates.</p>
CY2023Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	250000	usd
CY2023Q1	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	4959263	usd
	kitt	Total Balance Percentage TotalBalancePercentage	0.02	pure
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	1	pure
CY2022Q2	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.90	pure
CY2022	kitt	Customer Percentage CustomerPercentage	0.10	pure
CY2023Q2	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	1018707	usd
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	1499030	usd
CY2023Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	11517297	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	5167882	usd
CY2023Q2	us-gaap	Inventory Gross InventoryGross	12536004	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	6666912	usd
	kitt	Recognized Income Tax RecognizedIncomeTax	0.50	pure
CY2023Q2	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	17709	usd
	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	27593	usd
CY2022Q2	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	0	usd
	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	9848	usd
	us-gaap	Interest Costs Capitalized Adjustment InterestCostsCapitalizedAdjustment	536077	usd
	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	219531	usd
	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	85207	usd
	us-gaap	Interest Costs Capitalized Adjustment InterestCostsCapitalizedAdjustment	35376	usd
CY2023Q2	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	4847080	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Recent Accounting Pronouncements</i></b><i> – </i>In September 2022, the FASB issued ASU 2022-04, Liabilities – Supplier Finance Programs (Subtopic 405-60): Disclosure of Supplier Finance Program Obligations, which requires companies to disclose the use and impact of such programs on a company’s working capital, liquidity, and cash flow. We adopted this standard on January 1, 2023. We do not utilize Supplier Finance Programs and therefore no further disclosure is required. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In June 2016, the FASB issued ASU No. 2016-13, an amendment to ASC 326, <i>Financial Instruments - Credit Losses</i>, which changes the impairment model for certain financial assets that have a contractual right to receive cash, including trade and loan receivables. The new model requires recognition based upon an estimation of expected credit losses rather than recognition of losses when it is probable that they have been incurred. An entity will apply the amendment through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The Company has adopted this standard as of January 1, 2023, and there was no impact on its financial position, results of operations and cash flows upon adoption.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In March 2022, the FASB issued ASU No. 2022-02, an amendment to ASC 326, <i>Financial Instruments-Credit Losses</i>, which eliminates the accounting guidance for creditors in troubled debt restructuring. It also aligns conflicting disclosure requirement guidance in ASC 326 by requiring disclosure of current-period gross write-offs by year of origination. The amendment also adds new disclosures for creditors with loan refinancing and restructuring for borrowers experiencing financial difficulty. The Company has adopted this standard as of January 1, 2023, and there was no impact on its financial position, results of operations and cash flows upon adoption.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There are no other new accounting pronouncements that are expected to have a material impact on our condensed consolidated financial statements.</p>
CY2023Q2	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	1128115	usd
CY2022Q2	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	2989559	usd
	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	3948895	usd
	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	5225524	usd
	us-gaap	Accounts Receivable Purchase AccountsReceivablePurchase	1302494	usd
CY2022	us-gaap	Accounts Receivable Purchase AccountsReceivablePurchase	1622434	usd
CY2023Q2	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	9963	usd
CY2022Q4	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	9963	usd
CY2023Q2	kitt	Bad Debt Expens BadDebtExpens	0	usd
	kitt	Bad Debt Expens BadDebtExpens	0	usd
CY2022Q2	kitt	Bad Debt Expens BadDebtExpens	0	usd
	kitt	Bad Debt Expens BadDebtExpens	17827	usd
	us-gaap	Contract With Customer Asset Sale ContractWithCustomerAssetSale	37341	usd
	kitt	Revenue Recognize RevenueRecognize	8000000	usd
CY2023Q2	kitt	Contract Receivable Retainages Due One To Two Years ContractReceivableRetainagesDueOneToTwoYears	8	usd
CY2023Q2	kitt	Contract Receivable Retainages Due Two To Three Years ContractReceivableRetainagesDueTwoToThreeYears	2.6	usd
CY2023Q2	kitt	Contract Receivable Retainages Due Two To Four Years ContractReceivableRetainagesDueTwoToFourYears	5.4	usd
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	2454298	usd
	kitt	Antidilutive Securities Excluded From Computation Of Earnings Per Share Earnout Shares AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareEarnoutShares		shares
CY2023Q2	us-gaap	Prepaid Insurance PrepaidInsurance	919870	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	2392978	usd
CY2023Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	354088	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	199323	usd
CY2023Q2	us-gaap	Other Assets OtherAssets	6121038	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	5046599	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2320216	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2003341	usd
CY2023Q2	us-gaap	Construction In Progress Gross ConstructionInProgressGross	19814374	usd
CY2022Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	12974361	usd
CY2023Q2	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	21784483	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	15167367	usd
CY2023Q2	us-gaap	Compensated Absences Liability CompensatedAbsencesLiability	404364	usd
CY2022Q4	us-gaap	Compensated Absences Liability CompensatedAbsencesLiability	1501736	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	702944	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	794021	usd
CY2023Q2	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	201989	usd
CY2022Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	590936	usd
CY2023Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	1294305	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	171660	usd
CY2023Q2	kitt	Accrued Interest And Penalties AccruedInterestAndPenalties	4320690	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	385759	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	84624	usd
CY2023Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	7310051	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	3142977	usd
CY2023Q2	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	1200000	usd
	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	4320690	usd
CY2023Q1	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	3958645	usd
	kitt	Convertible Secured Debentures ConvertibleSecuredDebentures	36530320	usd
CY2022	kitt	Convertible Secured Debentures ConvertibleSecuredDebentures	36530320	usd
CY2023Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	36530320	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	36530320	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-18729826	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-20608202	usd
CY2023Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	17800494	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	15922118	usd
CY2023Q2	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.02	pure
CY2023Q2	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	36530320	usd
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	2922425	shares
	kitt	Inclusive Proceeds InclusiveProceeds	35800000	usd
	kitt	Fair Value Debenture Warrants FairValueDebentureWarrants	20949110	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	21679716	usd
	kitt	The Debentures Converted Description TheDebenturesConvertedDescription	The Debentures may be converted at each holder’s option at 120% of the principal amount at a conversion price of $15.00 or 2,922,425 shares of Common Stock, subject to certain adjustments including full ratchet anti-dilution price protections. Interest accrues on the outstanding principal amount of the Debentures at 5% per annum, payable quarterly.
	kitt	Exercisable Initially Par Share ExercisableInitiallyParShare	20
CY2023Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P10Y
CY2023Q2	us-gaap	Interest Income Debt Securities Trading Operating InterestIncomeDebtSecuritiesTradingOperating	970511	usd
	us-gaap	Interest Income Debt Securities Trading Operating InterestIncomeDebtSecuritiesTradingOperating	1878376	usd
	us-gaap	Debt Instrument Interest Rate Basis For Effective Rate DebtInstrumentInterestRateBasisForEffectiveRate	25.2%
	kitt	Discount Interest Rate DiscountInterestRate	0.15	pure
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	66374	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	208169	usd
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	104528	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	139315	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	207497	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	69191	usd
CY2023Q2	us-gaap	Variable Lease Cost VariableLeaseCost	96335	usd
CY2022Q2	us-gaap	Variable Lease Cost VariableLeaseCost	89016	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	105270	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	44508	usd
CY2023Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	200863	usd
CY2022Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	228331	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	312767	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	113699	usd
	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	204987	usd
	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	206042	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1384779	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	317208	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	524279	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	410158	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	992660	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	87214	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1516939	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	497372	usd
	kitt	Operating Lease Liabilities OperatingLeaseLiabilities	P11Y2M12D
CY2022	kitt	Operating Lease Liabilities OperatingLeaseLiabilities	P2Y2M12D
CY2023Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.139	pure
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.079	pure
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	220745	usd
	kitt	Antidilutive Securities Excluded From Computation Of Earnings Per Share Earnout Shares AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareEarnoutShares		shares
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	268483	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	290968	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	2476008	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3530747	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2013808	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1516939	usd
CY2023Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	7499993	shares
	kitt	Private Warrants Shares PrivateWarrantsShares	8624991	shares
	kitt	Common Stock Exceeds Price CommonStockExceedsPrice	16.5
	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	11.5
CY2023Q2	us-gaap	Other Liabilities OtherLiabilities	1677025	usd
	kitt	Private Warrants Description PrivateWarrantsDescription	The fair value of the Private Warrants was estimated using a Black-Scholes option pricing model using the following assumptions: stock price of $2.07, no assumed dividends, a risk-free rate of 4.27%, and implied volatility of 59.2%. The change in the value of the Private Warrants during the three and six months ended June 30, 2023, totaled $(23,799) and $(257,563), respectively, and was reported with other (income) expense in our condensed consolidated statements of operations.
CY2023Q2	us-gaap	Class Of Warrant Or Right Unissued ClassOfWarrantOrRightUnissued	2922425	shares
CY2023Q2	kitt	Warrant Exercisable Share WarrantExercisableShare	2922425	shares
CY2023Q2	kitt	Aggregate Shares AggregateShares	2922425	shares
CY2023Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	165713	shares
CY2023Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	165713	shares
CY2023Q2	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	165713	shares
CY2023Q2	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	29657015	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	26819502	usd
CY2023Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	590266	usd
	us-gaap	Stockholders Equity Other Shares StockholdersEquityOtherShares	7216908	shares
	kitt	Business Combination Shares BusinessCombinationShares	279464	shares
	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	3970266	shares
	kitt	Continuous Service Percentage ContinuousServicePercentage	0.25	pure
CY2023Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1138576	usd
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P2Y1M17D
	us-gaap	Debt Instrument Convertible Conversion Ratio1 DebtInstrumentConvertibleConversionRatio1	14.2069	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y6M18D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	91947	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	usd
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested	3673399	usd
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested	2577625	usd
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2752450	usd
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1794894	usd
	us-gaap	Share Based Goods And Nonemployee Services Transaction Tax Benefit ShareBasedGoodsAndNonemployeeServicesTransactionTaxBenefit	182234	usd
	us-gaap	Share Based Goods And Nonemployee Services Transaction Tax Benefit ShareBasedGoodsAndNonemployeeServicesTransactionTaxBenefit	0	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1214580	shares
	kitt	Vested Percentage VestedPercentage	0.51	pure
	kitt	Aggregate Of Shares AggregateOfShares	619438	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	3134677	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	4.73
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	246123	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	2.76
	kitt	Share Based Compensation Arrangement By Share Based Payment Shares Released ShareBasedCompensationArrangementByShareBasedPaymentSharesReleased	298531	shares
	kitt	Sharebased Compensation Arrangement By Sharebased Payment Released Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentReleasedWeightedAverageGrantDateFairValue	4.26
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	72636	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	4.73
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	3009633	shares
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	4.61
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	8953659	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P1Y7M17D
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1883833	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3077027	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	188657	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	388814	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39872864	shares
	kitt	Employees Gross Salaries Percentage EmployeesGrossSalariesPercentage	0.03	pure
CY2023Q2	us-gaap	Prescription Drug Benefit Effect Of Subsidy On Net Periodic Postretirement Benefit Cost1 PrescriptionDrugBenefitEffectOfSubsidyOnNetPeriodicPostretirementBenefitCost1	42165	usd
	us-gaap	Prescription Drug Benefit Effect Of Subsidy On Net Periodic Postretirement Benefit Cost1 PrescriptionDrugBenefitEffectOfSubsidyOnNetPeriodicPostretirementBenefitCost1	159506	usd
CY2022Q2	us-gaap	Prescription Drug Benefit Effect Of Subsidy On Net Periodic Postretirement Benefit Cost1 PrescriptionDrugBenefitEffectOfSubsidyOnNetPeriodicPostretirementBenefitCost1	84121	usd
	us-gaap	Prescription Drug Benefit Effect Of Subsidy On Net Periodic Postretirement Benefit Cost1 PrescriptionDrugBenefitEffectOfSubsidyOnNetPeriodicPostretirementBenefitCost1	162311	usd
	kitt	Investment And Securities Description InvestmentAndSecuritiesDescription	(i) $2,500,000 from related party Material Impact Fund II, L.P. (“Material Impact”) as their contribution to the PIPE Investment, (ii) $7,500,000 from related party Schlumberger Technology Corporation as their contribution to the PIPE Investment, (iii) $7,500,000 from related party Transocean Ltd. as their contribution to the PIPE Investment, and (iv) $5,102,000 from related party Material Impact and $29,591,600 from related party ATW pursuant to the Securities Purchase Agreement.
CY2023Q2	us-gaap	Accounts Payable Interest Bearing Interest Rate AccountsPayableInterestBearingInterestRate	0.05	pure
	us-gaap	Interest Expense Junior Subordinated Debentures InterestExpenseJuniorSubordinatedDebentures	1407018	usd
CY2023Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	165713	shares
CY2023Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	165713	shares
CY2023Q2	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	165713	shares
CY2023Q2	us-gaap	Trade Receivables Held For Sale Amount TradeReceivablesHeldForSaleAmount	0	usd
CY2022Q4	us-gaap	Trade Receivables Held For Sale Amount TradeReceivablesHeldForSaleAmount	21000	usd
CY2023Q2	us-gaap	Net Income Loss From Discontinued Operations Available To Common Shareholders Basic NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic	20673440	usd
CY2022Q2	us-gaap	Net Income Loss From Discontinued Operations Available To Common Shareholders Basic NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic	-3356956	usd
	us-gaap	Net Income Loss From Discontinued Operations Available To Common Shareholders Basic NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic	6534775	usd
	us-gaap	Net Income Loss From Discontinued Operations Available To Common Shareholders Basic NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic	-6860958	usd
CY2023Q2	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	1129509	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	21802949	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3356956	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	6534775	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-6860958	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39963266	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9669217	shares
CY2023Q2	us-gaap	Amount Of Dilutive Securities Stock Options And Restrictive Stock Units AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits	380204	usd
	us-gaap	Amount Of Dilutive Securities Stock Options And Restrictive Stock Units AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits	190102	usd
CY2023Q2	kitt	Amount Of Dilutive Securities Restricted And Performance Stock Units AmountOfDilutiveSecuritiesRestrictedAndPerformanceStockUnits	1079424	shares
	kitt	Amount Of Dilutive Securities Restricted And Performance Stock Units AmountOfDilutiveSecuritiesRestrictedAndPerformanceStockUnits	539712	shares
CY2023Q2	us-gaap	Amount Of Dilutive Securities Esop Convertible Preferred Stock AmountOfDilutiveSecuritiesESOPConvertiblePreferredStock	2922425	usd
CY2023Q2	kitt	Dilutive Securities Effect On Weighted Average Shares Used To Compute Diluted Eps DilutiveSecuritiesEffectOnWeightedAverageSharesUsedToComputeDilutedEPS	44345319	usd
CY2022Q2	kitt	Dilutive Securities Effect On Weighted Average Shares Used To Compute Diluted Eps DilutiveSecuritiesEffectOnWeightedAverageSharesUsedToComputeDilutedEPS	9669217	usd
	kitt	Dilutive Securities Effect On Weighted Average Shares Used To Compute Diluted Eps DilutiveSecuritiesEffectOnWeightedAverageSharesUsedToComputeDilutedEPS	40602678	usd
	kitt	Dilutive Securities Effect On Weighted Average Shares Used To Compute Diluted Eps DilutiveSecuritiesEffectOnWeightedAverageSharesUsedToComputeDilutedEPS	9669217	usd
CY2023Q2	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0.52	usd
CY2022Q2	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	-0.35	usd
	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0.16	usd
	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	-0.71	usd
CY2023Q2	kitt	Dilutive Securities Effect On Diluted Incomeloss Per Sharein Dollars Per Share DilutiveSecuritiesEffectOnDilutedIncomelossPerShareinDollarsPerShare	0.49	usd
CY2022Q2	kitt	Dilutive Securities Effect On Diluted Incomeloss Per Sharein Dollars Per Share DilutiveSecuritiesEffectOnDilutedIncomelossPerShareinDollarsPerShare	-0.35	usd
	kitt	Dilutive Securities Effect On Diluted Incomeloss Per Sharein Dollars Per Share DilutiveSecuritiesEffectOnDilutedIncomelossPerShareinDollarsPerShare	0.16	usd
	kitt	Dilutive Securities Effect On Diluted Incomeloss Per Sharein Dollars Per Share DilutiveSecuritiesEffectOnDilutedIncomelossPerShareinDollarsPerShare	-0.71	usd
CY2023Q2	kitt	Antidilutive Securities Excluded From Computation Of Earnings Per Share Stock Options AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareStockOptions	764296	shares
CY2022Q2	kitt	Antidilutive Securities Excluded From Computation Of Earnings Per Share Stock Options AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareStockOptions	3967959	shares
	kitt	Antidilutive Securities Excluded From Computation Of Earnings Per Share Stock Options AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareStockOptions	764296	shares
	kitt	Antidilutive Securities Excluded From Computation Of Earnings Per Share Stock Options AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareStockOptions	3967959	shares
CY2023Q2	kitt	Antidilutive Securities Excluded From Computation Of Earnings Per Share Restricted And Performance Stock Units AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareRestrictedAndPerformanceStockUnits	1480101	shares
	kitt	Antidilutive Securities Excluded From Computation Of Earnings Per Share Restricted And Performance Stock Units AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareRestrictedAndPerformanceStockUnits	1480101	shares
CY2023Q2	kitt	Antidilutive Securities Excluded From Computation Of Earnings Per Share AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare	18722425	usd
	kitt	Antidilutive Securities Excluded From Computation Of Earnings Per Share AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare	18722425	usd
CY2023Q2	kitt	Antidilutive Securities Excluded From Computation Of Earnings Per Share Earnout Shares AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareEarnoutShares	7499993	shares
	kitt	Antidilutive Securities Excluded From Computation Of Earnings Per Share Convertible Debt AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareConvertibleDebt	2922425	usd
	kitt	Antidilutive Securities Excluded From Computation Of Earnings Per Share Convertible Debt AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareConvertibleDebt	5299546	usd
CY2023Q2	kitt	Antidilutive Securities Excluded From Computation Of Earning Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningPerShareAmount	28466815	usd
CY2022Q2	kitt	Antidilutive Securities Excluded From Computation Of Earning Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningPerShareAmount	3967959	usd
	kitt	Antidilutive Securities Excluded From Computation Of Earning Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningPerShareAmount	23889247	usd
	kitt	Antidilutive Securities Excluded From Computation Of Earning Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningPerShareAmount	9267505	usd
CY2023Q2	kitt	Antidilutive Securities Excluded From Computation Of Earnings Per Share Convertible Debt AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareConvertibleDebt		usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	kitt	Service Related Party ServiceRelatedParty		usd
CY2022Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax		usd
CY2022Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2023Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
	us-gaap	Extinguishment Of Debt Gain Loss Income Tax ExtinguishmentOfDebtGainLossIncomeTax		usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities		usd
	us-gaap	Increase Decrease In Notes Payable Current IncreaseDecreaseInNotesPayableCurrent		usd
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods		usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods		usd
CY2022Q4	kitt	Accrued Interest And Penalties AccruedInterestAndPenalties		usd
CY2023Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent		usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent		usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding		usd
CY2022Q2	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax		usd
	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax		usd
	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax		usd
CY2022Q2	us-gaap	Amount Of Dilutive Securities Stock Options And Restrictive Stock Units AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits		usd
	us-gaap	Amount Of Dilutive Securities Stock Options And Restrictive Stock Units AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits		usd
CY2022Q2	kitt	Amount Of Dilutive Securities Restricted And Performance Stock Units AmountOfDilutiveSecuritiesRestrictedAndPerformanceStockUnits		shares
	kitt	Amount Of Dilutive Securities Restricted And Performance Stock Units AmountOfDilutiveSecuritiesRestrictedAndPerformanceStockUnits		shares
CY2023Q2	kitt	Warrants Warrants		shares
CY2022Q2	kitt	Warrants Warrants		shares
	kitt	Warrants Warrants		shares
	kitt	Warrants Warrants		shares
CY2023Q2	kitt	Earnout Shares EarnoutShares		shares
CY2022Q2	kitt	Earnout Shares EarnoutShares		shares
	kitt	Earnout Shares EarnoutShares		shares
	kitt	Earnout Shares EarnoutShares		shares
CY2022Q2	us-gaap	Amount Of Dilutive Securities Esop Convertible Preferred Stock AmountOfDilutiveSecuritiesESOPConvertiblePreferredStock		usd
	us-gaap	Amount Of Dilutive Securities Esop Convertible Preferred Stock AmountOfDilutiveSecuritiesESOPConvertiblePreferredStock		usd
	us-gaap	Amount Of Dilutive Securities Esop Convertible Preferred Stock AmountOfDilutiveSecuritiesESOPConvertiblePreferredStock		usd
CY2022Q2	kitt	Antidilutive Securities Excluded From Computation Of Earnings Per Share Restricted And Performance Stock Units AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareRestrictedAndPerformanceStockUnits		shares
	kitt	Antidilutive Securities Excluded From Computation Of Earnings Per Share Restricted And Performance Stock Units AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareRestrictedAndPerformanceStockUnits		shares
CY2022Q2	kitt	Antidilutive Securities Excluded From Computation Of Earnings Per Share AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare		usd
	kitt	Antidilutive Securities Excluded From Computation Of Earnings Per Share AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare		usd
CY2022Q2	kitt	Antidilutive Securities Excluded From Computation Of Earnings Per Share Convertible Debt AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareConvertibleDebt		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001849820

Files In Submission

Name	View Source	Status
0001213900-23-066523-index-headers.html	Edgar Link	pending
0001213900-23-066523-index.html	Edgar Link	pending
0001213900-23-066523.txt	Edgar Link	pending
0001213900-23-066523-xbrl.zip	Edgar Link	pending
f10q0623ex31-1_nauticusrobo.htm	Edgar Link	pending
f10q0623ex31-2_nauticusrobo.htm	Edgar Link	pending
f10q0623ex32-1_nauticusrobo.htm	Edgar Link	pending
f10q0623ex32-2_nauticusrobo.htm	Edgar Link	pending
f10q0623_nauticusrobo.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
kitt-20230630.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
kitt-20230630_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
kitt-20230630_lab.xml	Edgar Link	unprocessable
kitt-20230630_pre.xml	Edgar Link	unprocessable
kitt-20230630_def.xml	Edgar Link	unprocessable
f10q0623_nauticusrobo_htm.xml	Edgar Link	completed
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KITT
Nauticus Robotics, Inc. Stock $kitt

2023 Q3 Form 10-Q Financial Statement

#000121390023066523 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KITT Nauticus Robotics, Inc. Stock $kitt

2023 Q3 Form 10-Q Financial Statement

#000121390023066523 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KITT
Nauticus Robotics, Inc. Stock $kitt